Wall Street analysts expect that Emergent Biosolutions Inc (NYSE:EBS) will post earnings of $0.51 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Emergent Biosolutions’ earnings, with estimates ranging from $0.35 to $0.59. Emergent Biosolutions reported earnings per share of $0.73 during the same quarter last year, which suggests a negative year over year growth rate of 30.1%. The firm is expected to report its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Emergent Biosolutions will report full-year earnings of $2.33 per share for the current year, with EPS estimates ranging from $2.15 to $2.48. For the next financial year, analysts forecast that the firm will post earnings of $2.83 per share, with EPS estimates ranging from $2.18 to $3.59. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. During the same quarter last year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 118.5% on a year-over-year basis.
Emergent Biosolutions traded down $1.43, reaching $55.03, on Friday, Marketbeat reports. 300,839 shares of the company traded hands, compared to its average volume of 249,817. Emergent Biosolutions has a one year low of $32.48 and a one year high of $60.00. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.82 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 1.21 and a beta of 1.20.
In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,377 shares of the stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $51.15, for a total transaction of $70,433.55. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Abdun-Nabi sold 15,785 shares of the stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total value of $822,556.35. Following the sale, the chief executive officer now owns 197,343 shares in the company, valued at $10,283,543.73. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,538 shares of company stock worth $2,798,946. Company insiders own 16.50% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Emergent Biosolutions by 20.2% in the 2nd quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock worth $271,268,000 after buying an additional 901,882 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in shares of Emergent Biosolutions by 4,093.4% in the 1st quarter. Summit Trail Advisors LLC now owns 1,378,959 shares of the biopharmaceutical company’s stock worth $1,379,000 after buying an additional 1,346,075 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Emergent Biosolutions by 18.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock worth $57,610,000 after buying an additional 174,614 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Emergent Biosolutions by 29.6% in the 1st quarter. Millennium Management LLC now owns 917,065 shares of the biopharmaceutical company’s stock worth $48,283,000 after buying an additional 209,581 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Emergent Biosolutions by 2.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 755,948 shares of the biopharmaceutical company’s stock worth $38,167,000 after buying an additional 16,801 shares during the last quarter. Institutional investors and hedge funds own 82.65% of the company’s stock.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.